GlassScriptPhysician profile
Cindy Lynn Lamerson
NPI 1699763201
$8,525.44
in general payments reported to CMS, 2019-2025
32 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $777 · 2020: $517 · 2021: $1,025 · 2022: $1,288 · 2023: $1,471 · 2024: $1,984 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,634 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,633.79 |
| Education | $285.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,592.69 | 2019-2025 | |
| Lilly USA, LLC | $799.97 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $699.88 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $616.71 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $527.69 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Regeneron Healthcare Solutions, INC. | $459.94 | 2019-2025 | Dupixent |
| Pfizer INC. | $383.89 | 2020-2024 | |
| Amgen INC. | $375.98 | 2019-2025 | Otezla, Otezla |
| Almirall LLC | $356.97 | 2019-2023 | Seysara |
| Genzyme Corporation | $354.90 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $311.64 | 2023-2025 | Sotyktu |
| Allergan, INC. | $223.65 | 2019-2022 | |
| Galderma Laboratories, L.P. | $217.90 | 2019-2025 | Nemluvio |
| Ucb, INC. | $215.02 | 2019-2025 | Bimzelx |
| Hill Dermaceuticals, INC. | $172.99 | 2023-2024 | Tolak |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $171.53 | 2019-2024 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $131.22 | 2019-2023 | Jublia |
| Novartis Pharmaceuticals Corporation | $128.58 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $114.70 | 2020 | |
| Arcutis Biotherapeutics, INC. | $102.19 | 2023-2025 | Zoryve |
| Genentech USA, INC. | $93.10 | 2020-2024 | Erivedge |
| Mayne Pharma Commercial LLC | $88.96 | 2019 | |
| Biofrontera INC. | $81.44 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Prugen, INC. Pharmaceuticals | $72.62 | 2019-2020 | |
| Dermavant Sciences, INC. | $71.57 | 2023 | Vtama |
| Botanix Sb INC | $39.72 | 2025 | Sofdra |
| Mission Pharmacal Company | $29.24 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.66 | 2021 | |
| Organogenesis INC. | $23.31 | 2020 | |
| Organon LLC | $18.94 | 2025 | Vtama |
| Merz North America, INC. | $13.85 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $9.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Lamerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.